Top Markets
Coin of the day
Tianjin Ringpu Bio-Technology Co.,Ltd. Tianjin Ringpu Bio-Technology Co.,Ltd.

Tianjin Ringpu Bio-Technology Co.,Ltd.

300119
Rank in Stocks #8815
Established in 1998 and based in Tianjin, China, Tianjin Ringpu Bio-Technology... Established in 1998 and based in Tianjin, China, Tianjin Ringpu Bio-Technology Co.,Ltd. focuses on the research, development, manufacturing, and commercialization of a broad spectrum of animal health solutions. Their product portfolio includes veterinary biologicals, pharmaceutical formulations, functional feed additives, and active pharmaceutical ingredients (APIs) for the Chinese market. The company provides a wide array of vaccines and medications for livestock, particularly poultry and swine. They also offer a comprehensive line of pet care products, such as inactivated rabies vaccines, recombinant canine-alpha interferon, inhalation anesthetics like isoflurane and sevoflurane for dogs and cats, cefquinoxime sulfate injections for bacterial infections, and cardiac treatments including napril chewable tablets. For waterfowl, their specialized offerings include live and inactivated duck tempusu vaccines, purified egg yolk antibodies for gosling plague and duck viral hepatitis, duck infectious serositis inactivated vaccines, as well as injectable and soluble powder treatments like florfenicol and kanamycin. Furthermore, Ringpu develops antifungal products featuring natural plant extracts, immune polysaccharides, probiotics (such as Clostridium butyricum and Lactobacillus plantarum), antibacterial peptides, enzyme preparations, and acidulants. Their disinfection and cleaning range comprises potassium hydrogen persulfate composite powder, various quaternary ammonium compounds (e.g., benzyl trimethyl ammonium chloride, deca methyl ammonium bromide), sodium dichloroisocyanurate, and iodine glycerin solutions. The company's API production includes crucial ingredients like tilmicosin, tilmicosin phosphate, monbutone, tidiroxine, florfenicol, vonimulin hydrochloride, and gamimycin.
Share Price
$2.51
Last synced: 2026-08-28
Market Cap
$1.17B
Change (1 day)
0.58%
Change (1 year)
-20.26%
Country
CN
Trade Tianjin Ringpu Bio-Technology Co.,Ltd. (300119)

Category

Revenue for Tianjin Ringpu Bio-Technology Co.,Ltd. (300119)
Revenue in Aug 2026 TTM: 0
According to Tianjin Ringpu Bio-Technology Co.,Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Tianjin Ringpu Bio-Technology Co.,Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors